Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.37 |
| ▸ | PKM | P14618 | 6/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762034 | 0.81 | F2 (0.41) | F2PLAUALDH1A1PRSS1PRSS2 | |
| SCHEMBL8017305 | 0.70 | F2 (0.43) | F2PLAU | |
| SCHEMBL8028098 | 0.69 | F2 (0.43) | F2PLAUPRSS1PRSS2PRSS3 | |
| SCHEMBL6572898 | 0.68 | IDH1 (0.40) | F2PKMALDH1A1 | |
| SCHEMBL13696856 | 0.63 | F2 (0.44) | F2ALDH1A1 | |
| SCHEMBL7075389 | 0.61 | F10 (0.46) | F2ALDH1A1 | |
| SCHEMBL525390 | 0.61 | SRC (0.50) | F2 | |
| SCHEMBL22315304 | 0.60 | PTGES2 (0.44) | F2ALDH1A1 | |
| SCHEMBL6766786 | 0.60 | F2 (0.60) | F2ALDH1A1PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL8986751 | 0.60 | SRC (0.49) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | F2 612/4885PKM 764/4885MRGPRX1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.